Lindsay A. Lo

Lindsay A. Lo

Auto-generated profile, based on publicly available information

Lindsay A. Lo

Department of Public Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in European Journal of Internal Medicine
Verified
Journal Article
Open access
CMCaroline A. MacCallum
Caroline A. MacCallum
LLLindsay A. Lo
Lindsay A. Lo
Michael BoivinMichael Boivin
Michael Boivin
Medical cannabis use is increasing worldwide. Clinicians are commonly asked by patients to provide guidance on its safety and efficacy. Although there has been an increase in research on the role of medical cannabis for a number of different conditions, we found that there was a paucity of clear safety guidance on its use. We aim to address this issue by answering two pertinent clinician safety questions: 1 Can medical cannabis be safely used in this patient? 2. What strategies can be used to ensure that any harms from medical cannabis are mitigated? To address these questions, we reviewed available evidence and provided expert clinical opinion to summarize the fundamental components for evaluating medical cannabis safety and strategies to reduce risk from its use. Our review resulted in a safety-focused framework for medical cannabis initiation and utilization. We provide clear recommendations for patients being considered for cannabis (e.g. precautions, contraindications and drug interactions). Risk mitigation strategies such as appropriate chemovar (strain) selection, routes of administration, and dosing are reviewed. As with any other pharmacotherapy, we review the key components of monitoring and address potential issues that may arise while using medical cannabis. We propose a structured assessment and monitoring strategy that can be used by clinicians recomending cannabis (CRC) to guide patients through each step of their cannabis journey. This framework can be used to ensure that medical cannabis utilization is associated with the lowest possible risk to the patient.

17 August 2022 in Journal of Addictive Diseases
Verified
Journal Article
Closed access
LLLindsay A. Lo
Lindsay A. Lo
CMCaroline A. MacCallum
Caroline A. MacCallum
JYJade C. Yau
Jade C. Yau
BABarr Alasdair
Barr Alasdair
Smoking cannabis in medical users is associated with exposure to harmful toxins. It is important to characterize cannabis-use profiles and risk-factors for medical cannabis users who smoke cannabis. 100 members of a medical cannabis dispensary with mental health concerns were interviewed in detail about their cannabis use. Forty seven percent of participants preferred smoking only, 18% preferred vaporizing, 25% preferred both smoking and vaping, and 10% preferred oral ingestion methods. Smokers differed from other users in multiple ways, including a greater preference for THC-dominant chemovars, and more frequent and greater amount of cannabis consumption. Smoking was also associated with greater rates of alcohol use disorder. These results may inform harm-reduction approaches to decrease the number of individuals smoking cannabis and use less harmful methods of medical cannabis ingestion.

17 June 2023 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Open access
KBKatherine Bailey
Katherine Bailey
LLLindsay A. Lo
Lindsay A. Lo
BCBianca Chauhan
Bianca Chauhan
FFFatima Formuli
Fatima Formuli
JPJared R. Peck
Jared R. Peck
TBTara A. Burra
Tara A. Burra
Measurement-based care (MBC) is the clinical practice of using patient-reported symptom measurement to inform treatment decisions. MBC has been shown to improve patient outcomes and quality of care in outpatient psychiatry. Despite these benefits, MBC is not routinely used in most psychiatric outpatient settings. This quality improvement (QI) project aimed to achieve 75% completion of symptom scales using an online MBC platform in a general psychiatry clinic in Toronto, Canada, by June 2022. The QI team used the Model for Improvement methodology. The main outcome measure was completion of symptom scales using an online MBC platform. Process measures included counts of invitations to join the MBC platform, counts of online MBC account creation, and counts of symptom scale assignment by clinicians. Balancing measures included administrative task completion and physician workload assessment. Stakeholder interviews explored barriers and facilitators to MBC utilization. Completion of symptom scales increased from 7/65 (10.8%) preintervention to 40/70 (57.1%) during the 26-week intervention. Clinician reminders and coaching clinicians about how to incorporate MBC into the care process facilitated uptake of MBC. Stakeholders identified several barriers to implementation, particularly physician attitudes toward MBC and perceived administrative burden. Completion of symptom scales increased over the course of this QI initiative. Successful implementation of MBC in general psychiatry outpatient settings requires the availability of a broad range of measurement scales given the diversity of mental health diagnoses. Implementation must also consider health equity, including access to technology and availability of symptom scales in multiple languages.

21 September 2022 in Psychiatry and Clinical Psychopharmacology
Verified
Journal Article
Open access
LLLindsay A. Lo
Lindsay A. Lo
CMCaroline A. MacCallum
Caroline A. MacCallum
JYJade C. Yau
Jade C. Yau
WPWilliam J. Panenka
William J. Panenka
BABarr Alasdair
Barr Alasdair
Addiction,behavioral addiction,cannabis,psychiatry,psychopharmacology

6 August 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MBMichelle J. Blumberg
Michelle J. Blumberg
LLLindsay A. Lo
Lindsay A. Lo
GHGeoffrey W. Harrison
Geoffrey W. Harrison
ADAlison Dodwell
Alison Dodwell
SISamantha H. Irwin
Samantha H. Irwin
MOMary C. Olmstead
Mary C. Olmstead
Coronavirus (COVID-19) lockdowns provided a unique opportunity to examine how changes in the social environment impact mental health and wellbeing. We addressed this issue by assessing how perceived social support across COVID-19 restrictions alters alcohol and cannabis use in emerging adults, a population vulnerable to adverse outcomes of substance use. Four hundred sixty-three young adults in Canada and the United States completed online questionnaires for three retrospective time points: Pre-Covid, Lockdown and Eased Restrictions. Sociodemographic factors, perceived social support, and substance use were assessed. Overall, alcohol use decreased while cannabis use increased during Lockdown. Interestingly, social support negatively predicted alcohol use and positively predicted cannabis use during Lockdown. These findings suggest a difference in motives underlying alcohol and cannabis use in emerging adults. Importantly, these changes were not sustained when restrictions eased, suggesting that emerging adults exhibit resiliency to the impacts of COVID-19 restrictions on substance use.

30 June 2023 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
ESElizabeth N. R. Schjelderup
Elizabeth N. R. Schjelderup
CMCaroline A. MacCallum
Caroline A. MacCallum
LLLindsay A. Lo
Lindsay A. Lo
JDJessie Dhillon
Jessie Dhillon
ACApril Christiansen
April Christiansen
BABarr Alasdair
Barr Alasdair
Aim: Traumatic brain injury (TBI) is a common neurological condition, which can present with a wide range of neuropsychological symptoms. Treating this broad spectrum of symptoms represents a significant medical challenge. In part because of this, there is growing interest in the use of medical cannabis to treat the sequelae of TBI, as medical cannabis has been used to treat multiple associated conditions, such as pain. However, medical cannabis represents a heterogeneous collection of therapies, and relatively little is known about their effectiveness in treating TBI symptoms. The aim of the present study was therefore to assess medical cannabis use in patients with TBI. Methods: In the present study, a retrospective chart review was conducted of patterns of cannabis use and TBI symptoms in individuals who used medical cannabis to treat TBI-related symptoms. All subjects were recruited from a medical cannabis clinic, where cannabis was authorized by physicians, using licensed cannabis products. A total of 53 subjects provided written consent to have their charts reviewed. Results: Neuropsychiatric conditions, including depression, pain, and anxiety were frequent in this group. The most common forms of medical cannabis consumption at intake included smoking, vaping, and oral ingestion. Patients used a combination of high tetrahydrocannabinol (THC)/low cannabidiol (CBD) and low THC/high CBD products, typically 1–3 times per day. Medical cannabis appeared to be relatively well-tolerated in subjects, with few serious side effects. At follow-up, subjects self-reported improvements in TBI symptoms, although these were not statistically significant when assessed using validated questionnaires. Conclusions: Overall findings indicate modest potential benefits of medical cannabis for TBI, but further research will be required to validate these results.